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ABSTRACT
Flavin-containingmonooxygenase 3 (FMO3) is knownprimarily as an
enzyme involved in the metabolism of therapeutic drugs. On a daily
basis, however, we are exposed to one of the most abundant
substrates of the enzyme trimethylamine (TMA), which is released
fromvarious dietary components by the action of gut bacteria. FMO3
converts the odorous TMA to nonodorous TMA N-oxide (TMAO),
which is excreted in urine. Impaired FMO3 activity gives rise to the
inherited disorder primary trimethylaminuria (TMAU). Affected indi-
viduals cannot produce TMAO and, consequently, excrete large
amounts of TMA. A dysbiosis in gut bacteria can give rise to
secondary TMAU. Recently, there has been much interest in FMO3
and its catalytic product, TMAO, because TMAO has been implicated
in various conditions affecting health, including cardiovascular
disease, reverse cholesterol transport, and glucose and lipid
homeostasis. In this review, we consider the dietary components
that can give rise to TMA, the gut bacteria involved in the production
of TMA from dietary precursors, the metabolic reactions by which
bacteria produce and use TMA, and the enzymes that catalyze the
reactions. Also included is information on bacteria that produce
TMA in the oral cavity and vagina, two key microbiome niches that
can influence health. Finally, we discuss the importance of the
TMA/TMAO microbiome-host axis in health and disease, consid-
ering factors that affect bacterial production and host metabo-
lism of TMA, the involvement of TMAO and FMO3 in disease, and
the implications of the host-microbiome axis for management
of TMAU.
Introduction
Flavin-containing monooxygenases (FMOs) (EC 1.14.13.8) catalyze
the NADPH-dependent oxidative metabolism of a wide array of foreign
chemicals, including drugs, dietary-derived compounds, and environ-
mental pollutants (Krueger and Williams, 2005). Humans possess five
functional FMO genes: FMO1, 2, 3, 4, and 5 (Hernandez et al., 2004;
Phillips et al., 2007). The main site of expression of FMO3 is the liver
(Dolphin et al., 1996); however, high expression levels have also been
observed in the skin of certain individuals (Janmohamed et al., 2001).
The FMO3 gene is switched on in human liver at birth and can take
several years for the gene to attain maximum expression as the liver
develops to its full functional capacity (Koukouritaki et al., 2002).
Drug substrates for FMO3 include the antipsychotic olanzapine
(Söderberg et al., 2013), the antiestrogen tamoxifen (Parte and Kupfer,
2005), the gastroprokinetic agent itopride (Mushiroda et al., 2000), and
the H2-receptor antagonist cimetidine (Cashman et al., 1995). Substrates
undergoN- or S-oxygenation; generally, this is a detoxification route and
the products are excreted in urine, but some chemicals are converted to a
more active or toxic form (Krueger andWilliams, 2005). Retroreduction
of the oxygenated product can occur, creating a pool of drug that can be
recycled (Cashman, 2008). The importance of FMO3 in detoxification
and bioactivation of xenobiotics has recently been reviewed (Cruciani
et al., 2014). The FMO3 gene is highly polymorphic (Phillips et al.,
2007), and genetic variants that are common in the general population
are known to influence drug metabolism (Phillips et al., 2007; Söderberg
et al., 2013; Zhou et al., 2014).
FMO3 has an important relationship with the gut microbiome, with an
abundant nondrug substrate, trimethylamine (TMA), being derived from
dietary components by the action of gut microbes (Seim et al., 1985; Al-
Waiz et al., 1992). TMA is rapidly absorbed and is converted in the liver
to trimethylamine N-oxide (TMAO) (Higgins et al., 1972). Of the five
functional FMOs of humans (FMOs 1–5), only FMO3 effectively
catalyzes the conversion of TMA to TMAO (Lang et al., 1998). FMO3 is
thus an excellent example of a protein that participates in host-gut
microbiomemetabolic interactions (Nicholson et al., 2012). Rare genetic
variants of the FMO3 gene that abolish or severely impair activity of the
enzyme give rise to the inherited disorder primary trimethylaminuria
(TMAU) (Phillips and Shephard, 2008) because of inefficient conver-
sion of microbiome-derived odorous TMA to nonodorous TMAO.
Recently, there has been much interest in FMO3 and its catalytic
product TMAO. This is because TMAO has been implicated in various
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conditions affecting health, including cardiovascular disease, reverse
cholesterol transport, and glucose and lipid homeostasis (Wang et al.,
2011; Bennett et al., 2013; Koeth et al., 2013; Tang et al., 2013; Gao
et al., 2014; Obeid et al., 2016). The microbial origin of TMA is of great
interest as we begin to fully appreciate the importance of our micro-
biomes for health and well-being. Knowledge of the microbial species
that give rise to TMA would contribute greatly to our understanding of
the consequences for human health of the complex interrelationships of
diet, the microbiome, and the capacity for FMO3-catalyzed conversion
of TMA to TMAO.
In this review, we first describe the origins and metabolic fate of TMA
and outline the basis and consequences of TMAU.We then consider the
dietary components that can give rise to TMA, the gut bacteria involved
in the production of TMA from dietary precursors, the metabolic
reactions by which bacteria produce and use TMA, and the enzymes that
catalyze the reactions. Also included is information on bacteria that
produce TMA in the oral cavity and vagina, two key microbiome niches
that can influence health, and on noncommensal bacteria that pro-
duce TMA. Finally, we discuss the importance of the TMA/TMAO
microbiome-host axis in health and disease, considering factors that
affect bacterial production and host metabolism of TMA, the in-
volvement of TMAO and FMO3 in disease and the implications of the
host-microbiome axis for management of TMAU.
Origins and Metabolic Fate of TMA
The discovery and properties of TMA have been recently reviewed
(Mitchell and Smith, 2016). TMA is an indicator of food spoilage,
particularly of fish and milk. As early as the 1930s Beatty showed that
TMA was produced during fish spoilage (Beatty, 1938). The TMA is
derived from bacterially mediated reduction of TMAO (Barrett and
Kwan, 1985), which is present in large quantities in marine fish (Zhang
et al., 1999).
The requirement of bacterial action for the production of TMA from
the diet in vivo is demonstrated by the failure of germ-free rats fed
carnitine (Seim et al., 1985), or of germ-free or antibiotic-treated mice
fed a normal diet, to excrete TMA in their urine (Al-Waiz et al., 1992).
TMA is derived from the diet by microbial degradation of precursors
found in, for example, marine fish, eggs, offal, soya beans, peas, and red
meat (Zhang et al., 1999; Zeisel et al., 2003). Once liberated, TMA is
rapidly absorbed through the gut wall and transported to the liver, where
it is converted to nonodorous TMAO, which is then rapidly cleared in
the urine (Al-Waiz et al., 1987a). Analysis in vitro of heterologously
expressed FMOs revealed that, at physiologic pH, N-oxygenation of
TMA is catalyzed by FMO3, with a KM of 28 mM and an apparent kcat
of.30 minutes21 (Lang et al., 1998). Other FMOs are far less effective
in catalyzing this reaction: FMO1, FMO2, and FMO4, none of which is
expressed in adult human liver (Phillips et al., 2007), exhibit apparent
kcats of 0.1, 1.0, and 0.1minute
21, respectively, whereas FMO5, the only
other form of FMO expressed in the adult human liver (Phillips et al.,
2007), is unable to catalyze the reaction (Lang et al., 1998). FMO1,
which is expressed in human kidney (Dolphin et al., 1991), can catalyze
TMA N-oxygenation, with an apparent kcat of 5 minutes
21, but only at
substrate concentrations of 5 mM (Lang et al., 1998), which are unlikely
to be relevant for metabolism of TMA in vivo. The importance of FMO3
for the metabolism of TMA in vivo is demonstrated by the marked
reduction in the ability toN-oxygenate TMAof individuals homozygous
or compound heterozygous for mutations that severely impair FMO3
activity (Dolphin et al., 1997, 2000; Treacy et al., 1998).
In addition to N-oxygenation, rat liver microsomes carry out
demethylation of TMA, but the latter reaction is much less efficient
(Gut and Conney, 1991). Demethylation of TMA in rat liver was shown
to be catalyzed by a different FMO from that which catalyzes production
of the N-oxide (Gut and Conney, 1993). This FMO is probably FMO1,
whose gene is expressed in the liver of rodents and other mammals, but
not in adult human liver (Dolphin et al., 1991). In human volunteers, the
demethylation product was found in low amounts and only in those
dosed with high amounts of TMA (Al-Waiz, et al., 1987b). Conse-
quently, in humans FMO3-catalyzed N-oxygenation is by far the most
important route of metabolism of TMA.
Since microbial diversity studies have entered the era of high-
throughput sequencing and in silico analysis, more insight has been
gained into the composition of the human gut microbiota; however,
studies based on bacterial cultivation are still the main source for
information about themetabolic capacities of themicrobiota. Combining
what is being uncovered about the composition of the human microbiota
with what is known of the functional activity of its components enables
identification of microbial metabolic pathways by which TMA can be
produced or metabolized in the human gut.
TMAU, a Deficiency of FMO3
In humans, mutations that abolish or severely impair the activity of
FMO3 cause the inherited disorder primary TMAU (Dolphin et al., 1997;
Hernandez et al., 2003). Affected individuals have a severely reduced
ability to convert TMA to TMAO and, consequently, excrete large
amounts of odorous TMA in their urine, sweat, and breath (Ayesh et al.,
1993). Although the disorder has no overt physiologic effects on patient
health, it can have profound psychologic and social consequences,
resulting in a severe loss of quality of life, in extreme cases giving rise to
clinical depression and suicidal tendencies (Mitchell and Smith, 2001;
Shephard et al., 2015, [Phillips IR and Shephard EA. Primary
trimethylaminuria. GeneReviews at GeneTests: Medical Genetics In-
formation Resource (database online): University of Washington,
1997––2015 available at http://www.ncbi.nlm.nih.gov/books/NBK1103/,
updated 2015]. In terms of drug metabolism, TMAU individuals have
impaired metabolism of the FMO3 drug substrate benzydamine
(Mayatepek et al., 2004). Since the first discovery of a mutation known
to cause TMAU (Dolphin et al., 1997), many different causative
mutations have been identified (Phillips et al., 2007; Yamazaki and
Shimizu, 2013). A catalog of variants of the FMO3 gene and their effect
on the ability of FMO3 to catalyze the oxygenation of TMA and drug
substrates of the enzyme can be accessed at the FMO3 locus-specific
mutation database (http://databases.lovd.nl/shared/genes/FMO3).
Production of large amounts of TMA, as a result of gutmicrobial action,
exacerbates the symptoms of primary TMAU. In addition, overproduction
of TMA, as a consequence of a dysbiosis of the gut microbiome, can give
rise to a nongenetic form of the disorder, known as secondary TMAU
(Mitchell and Smith, 2001). Therefore, a better understanding of the
bacterial species that produce TMA in the gut may provide insights into
why some individuals develop secondary TMAU in the absence of
impaired N-oxygenation of TMA (Shimizu et al., 2014) and offers the
potential to develop improved strategies for the management and
treatment of both primary and secondary forms of the disorder.
Dietary Precursors of TMA and the Bacteria Involved in its
Production in the Gut
TMAO. TMAO, the oxygenated product of TMA, is itself a dietary
constituent that can give rise to TMA in the gut. Marine fish contain the
highest amounts of TMAO (up to 3 mg/g) of any food source (Mitchell
et al., 2002). The TMAO is thought to act as an osmolyte that allows
adaptation to changes in salinity (Pang et al., 1977) and hydrostatic
pressure (Zerbst-Boroffka et al., 2005). It is estimated that about 50% of
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consumed TMAO is not metabolized and passes through the body
unchanged to be excreted in the urine (Zhang et al., 1999). In the human
gut, the remainder of the TMAO is reduced to TMA by bacterial TMAO
reductase (EC 1.7.2.3) (Kwan and Barrett, 1983) (Fig. 1). Examples of
bacteria that produce TMA from TMAO are given in Table 1.
Choline. Choline is an essential dietary nutrient, which can function
as a precursor for the synthesis of phospholipids, including phosphati-
dylcholine, that are essential components of membranes, and of the
neurotransmitter acetylcholine. It is present in high quantities in a variety
of foodstuffs, for example, beef liver, cauliflower, and peanuts (Zeisel
et al., 2003), and high concentrations of free choline are present in
human milk and in soya bean–derived milk formulae (Zeisel, 1990).
Choline is usually ingested as lecithin (also known as phosphatidylcho-
line), however, in which the choline moiety is covalently bound to a
phosphatidate (a phosphoglycerol attached to two fatty acids) (Hirsch
et al., 1978). Interconversion of lecithin and choline is bidirectional,
conversion of lecithin to choline being catalyzed by phospholipase D
(EC 3.1.4.4) and the first step in the conversion of choline to lecithin by
choline kinase (EC 2.7.1.32) (Fig. 1).
Free choline is absorbed throughout the small intestine and is
subsequently integrated into cell membranes or actively taken up
by the liver, where it can be converted to betaine, phosphocholine, or
lecithin (Zeisel, 1990). High amounts of choline may exceed the
absorptive capacity and pass through to the large intestine, however,
where it is metabolized to methylamines by microbial action (Zeisel
et al., 1983). Choline is a quaternary ammonium compound containing a
trimethylammonium moiety. Thus, it can act as a precursor for TMA
(Zeisel et al., 1989; Chalmers et al., 2006). The bacterial conversion of
choline to TMA involves the cleavage of the carbon-nitrogen bond of
choline, producing TMA and acetaldehyde (Hayward and Stadtman,
1959). Craciun and Balskus (2012) proposed that a glycyl radical
enzyme CutC (EC 4.3.99.4), encoded by the bacterial choline utilization
gene cluster (cut), might act as a choline TMA-lyase to catalyze this
initial step in choline degradation (Fig. 1). This was confirmed by
demonstrating that deletion of cutC in Desulfovibrio desulfuricans
abolished the ability of the organism to produce TMA from choline.
Bioinformatics analysis revealed cutC homologs in 89 bacterial ge-
nomes. The homologs are not distributed evenly among the major
bacterial phyla of the human gut, being present in Firmicutes, Actino-
bacteria, and Proteobacteria spp. but absent from Bacteroidetes
(Craciun and Balskus, 2012). Table 1 shows bacteria known to be
associated with formation of TMA via choline degradation.
Carnitine. Carnitine plays a key role inmetabolism, being involved in
the transport of long-chain fatty acids from the cytosol into mitochondria.
Carnitine is a quaternary ammonium compound that can be synthesized
in the body from methionine and lysine, with its immediate precursor
being g-butyrobetaine (Feller and Rudman, 1988). L-carnitine is present
in red meat and dairy products (Feller and Rudman, 1988), and it is
estimated that the average nonvegetarian American consumes 100–
300mg/day (Feller and Rudman, 1988). Of dietary carnitine, about half is
absorbed from the intestine, and the other half is metabolized by gut flora,
eventually resulting in the excretion of TMAO and g-butyrobetaine in
urine and feces, respectively (Rebouche andChenard, 1991). Gut bacteria
are thought to cleave the 3-hydroperoxybutyryl moiety from L-carnitine
to produce TMA (Meadows and Wargo, 2015). This pathway has been
observed in several bacteria, including Serratia marascescens and
Acinetobacter calcoaceticus (Meadows and Wargo, 2015). Using
bioinformatics approaches, Zhu et al. (2014) identified a two-
component oxygenase/reductase Rieske-type enzyme, encoded by
cntAB, that catalyzed the formation of TMA from carnitine (see Fig. 1).
Fig. 1. Metabolic pathways for the production and metabolism of TMA by the human microbiota. TMA can be produced from TMAO in a reaction catalyzed by TMAO
reductase. Choline, either in its free form or released from lecithin (phosphatidylcholine), contributes to the formation of TMA directly, via the action of choline-TMA lyase,
encoded by the choline utilization cluster (cutC), or potentially indirectly, via conversion to betaine. Similarly, L-carnitine, present in red meat or derived from
g-butyrobetaine, contributes to TMA formation directly via the action of a Rieske-type carnitine reductase/oxidase (cntAB), or potentially indirectly, via conversion to
betaine or to g-butyrobetaine. Betaine can potentially contribute to TMA formation directly, via the action of a betaine reductase, or indirectly, via conversion to
dimethylglycine, which could be metabolized to TMA via a hypothetical decarboxylation. TMA can be produced from ergothioneine via the action of ergothionase. TMA
itself can be oxidized to TMAO, via the action of TMA monooxygenase. Asterisks represent multistep pathways. Bold text, TMA and its precursors and metabolites. Plain
text, enzymes that catalyze reactions in the pathways. Based on Zeisel, 1990; Kleber, 1997; Serra et al., 2002; Wood et al., 2010; Craciun and Balskus, 2012; Caspi et al.,
2014; Zhu et al., 2014.
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Both components are required for catalysis of electron transfer and
degradation of carnitine to TMA. Deletion of cntAB in A. calcoaceticus
rendered the microbe incapable of producing TMA. As is the case for
cutC in choline metabolism (Craciun and Balskus, 2012), cntAB is
distributed unevenly among the major bacterial phyla, being present in
Proteobacteria (mainly Gammaproteobacteria) and Firmicutes and
absent from Bacteroidetes spp. (Zhu et al., 2014).
In addition to generating TMA directly from L-carnitine, it has been
suggested that gut bacteria can also convert g-butyrobetaine to TMA.
Most studies consider g-butyrobetaine to be an intermediary metabolite
produced during the biosynthesis of L-carnitine, by a reaction catalyzed
by g-butyrobetaine hydroxylase (EC 1.14.11.1); however, the gut
microbiota may also be able to produce g-butyrobetaine from catabolism
of L-carnitine by a reaction catalyzed by g-butyrobetainyl-CoA:
carnitine-CoA transferase (EC 2.8.3.21) (Rebouche and Seim, 1998;
Caspi et al., 2014). Koeth et al. (2014) showed that g-butyrobetaine,
obtained through oral g-butyrobetaine or L-carnitine supplementation,
can bemetabolized bymicrobes to produce TMA and identified the gene
pair yeaW/yeaX as encoding an enzyme that catalyzes this reaction
in vitro. The enzyme, termed a carnitine TMA lyase (see Fig. 1), can also
catalyze production of TMAdirectly from choline, betaine, and carnitine
(Koeth et al., 2014). Table 1 shows bacteria known to be associated with
the formation of TMA via carnitine degradation.
Betaine. Betaine, or trimethylglycine, plays an important role as a
methyl donor in the betaine homocysteine methyltransferase pathway
(Obeid, 2013). It is present in high concentrations in various foodstuffs, for
example, wheat bran, wheat germ, and spinach (Zeisel et al., 2003). The
daily intake of betaine varies from;30–400 mg/d (Obeid, 2013). Betaine
TABLE 1
Bacteria that produce trimethylamine (TMA) from various substrates
Phylum Genus or Species References
TMA N-oxide
Actinobacteria Micrococcus Robinson et al., 1952
Mobiluncus Cruden and Galask, 1988
Firmicutes Bacillus Robinson et al., 1952
Clostridium Robinson et al., 1952
Staphylococcus Robinson et al., 1952
Sarcina Robinson et al., 1952
Streptococcus Robinson et al., 1952
Proteobacteria Alcaligenes Robinson et al., 1952
Campylobacter Sellars et al., 2002
Citrobacter Lin and Hurng, 1989
Escherichia Robinson et al., 1952; Ishimoto and Shimokawa, 1978; Cox and Knight, 1981; Takagi et al., 1981;
Easter et al., 1982; Lin and Hurng, 1989; Denby et al., 2015
Proteus Robinson et al., 1952; Strøm et al., 1979; Stenberg et al., 1982
Pseudomonas Robinson et al., 1952; Lee et al., 1977; Easter et al., 1982; Chen et al., 2011
Choline
Actinobacteria Mobiluncus Cruden and Galask, 1988
Olsenella Craciun and Balskus, 2012; Martínez-del Campo et al., 2015
Bacteroidetes Bacteroides Cruden and Galask, 1988
Firmicutes Anaerococcus Craciun and Balskus, 2012; Romano et al., 2015
Clostridium Robinson et al., 1952; Bradbeer, 1965; Fiebig and Gottschalk, 1983; Möller et al., 1986; Craciun and
Balskus, 2012; Martínez-del Campo et al., 2015; Romano et al., 2015
Desulfitobacterium Craciun and Balskus, 2012
Enterococcus Simenhoff et al., 1976
Streptococcus Robinson et al., 1952; Simenhoff et al., 1976; Chao and Zeisel, 1990; Craciun and Balskus, 2012;
Martínez-del Campo et al., 2015
Proteobacteria Desulfovibrioa Hayward and Stadtman, 1959, 1960; Baker et al., 1962; Bradbeer, 1965; Fiebig and Gottschalk, 1983;
Craciun and Balskus, 2012
Edwardsiella Romano et al., 2015
Enterobacterb Eddy, 1953; Craciun and Balskus, 2012
Escherichia Craciun and Balskus, 2012; Martínez-del Campo et al., 2015; Romano et al., 2015
Klebsiellab Eddy, 1953; Craciun and Balskus, 2012; Kuka et al., 2014; Kalnins et al., 2015;
Martínez-del Campo et al., 2015
Proteus Seim et al., 1982a; Craciun and Balskus, 2012; Kuka et al., 2014; Martínez-del Campo et al., 2015;
Romano et al., 2015
Providencia Craciun and Balskus, 2012; Romano et al., 2015
Pseudomonas Robinson et al., 1952; Kleber et al., 1978
Yokenella Craciun and Balskus, 2012
Carnitine
Proteobacteria Acinetobacter Kleber et al., 1977; Seim et al., 1982b; Miura-Fraboni et al., 1982; Ditullio et al., 1994; Zhu et al., 2014
Citrobacter Zhu et al., 2014
Escherichia Zhu et al., 2014
Klebsiella Kuka et al., 2014; Zhu et al., 2014
Proteus Seim et al., 1982a
Pseudomonas Kleber et al., 1978; Miura-Fraboni et al., 1982
Betaine
Firmicutes Clostridium Naumann et al., 1983; Möller et al., 1986
Eubacterium Zindel et al., 1988; Hormann and Andreesen, 1989
Sporomusa Möller et al., 1986; Hormann and Andreesen, 1989
Ergothioneine
Proteobacteria Alcaligenes Yanasugondha and Appleman, 1957; Kelly and Appleman, 1961
Escherichia Wolff, 1962
aSynonym: Vibrio cholincus.
bInitially observed as Aerobacter but reassigned to genera Enterobacter and Klebsiella.
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can also be biosynthesized, in both the human host and in gut bacteria, by
oxidation of choline or carnitine. The oxidation of choline to betaine
involves an intermediate conversion to betaine aldehyde, catalyzed by
choline dehydrogenase (EC 1.1.99.1), which in turn is converted to betaine
in a reaction catalyzed by betaine aldehyde dehydrogenase (EC 1.2.1.8)
(Andresen et al., 1988) (Fig. 1). L-carnitine can be converted to betaine via
a multistep pathway, the first reaction of which is catalyzed by L-carnitine
dehydrogenase (EC 1.1.108) (Meadows and Wargo, 2015) (Fig. 1).
There are several catabolic pathways for betaine (Fig. 1). One involves
demethylation of betaine to dimethylglycine, in a reaction catalyzed by
glycine betaine transmethylase (EC 2.1.1.5) (Wood et al., 2010; Caspi
et al., 2014). Dimethylglycine could be metabolized to TMA via a
hypothetical decarboxylation (Wood et al., 2010). Betaine can also
function as an electron acceptor in a coupled reduction-oxidation reaction
(i.e., Stickland reaction), catalyzed by betaine reductase (EC 1.21.4.4), in
which it is reduced and cleaved to produce TMA and acetate (Naumann
et al., 1983). Table 1 shows bacteria associated with the formation of
TMA through betaine degradation.
Ergothioneine. Ergothioneine, a biogenic amine, is a derivative of
histidine. Production of ergothioneine is common among fungi and in
certain bacteria, such as Actinobacteria, Cyanobacteria, Bacteroidetes,
and Proteobacteria spp. (Seebeck, 2010; Pfeiffer et al., 2011).
Ergothioneine is also present in mammals, where it is concentrated
in specific tissues or cells, such as kidney, liver, and erythrocytes
(Cheah and Halliwell, 2012). Mammals lack the ability to synthesize
ergothioneine, however, and humans derive the compound exclusively
from dietary sources such as mushrooms (bolete and oyster), some meat
products (kidney and liver), and some plant products (e.g., black beans,
red beans, oat bran) (Ey et al., 2007). The biologic role of ergothioneine
in humans is unknown, but it is thought to have antioxidant and
cytoprotectant properties (Cheah and Halliwell, 2012). When grown on
ergothioneine, some bacteria are able to use the compound as a sole
source of nitrogen, carbon, or energy. The degradation of ergothioneine,
catalyzed by ergothionase (EC 4.3.3.-), yields TMA and thiolurocanic
acid (Muramatsu et al., 2013) (Fig. 1). Table 1 shows bacteria associated
with the production of TMA from ergothioneine.
Metabolism of TMA by Gut Bacteria
Two pathways for microbial metabolism of TMA have been proposed
(Colby and Zatman, 1973). One involves the sequential oxygenation of
TMA and demethylation of its oxygenated form to yield dimethylamine
and formaldehyde (Fig. 2). This pathway is mediated by a trimethyl-
amine monooxygenase (EC 1.14.13.148) and a trimethylamine-oxide
aldolase (EC 4.1.2.32) and has been demonstrated to occur in
Pseudomonas aminovorans (Large et al., 1972; Boulton et al., 1974),
Bacillus (Myers and Zatman, 1971), and methylotrophs such as
Hyphomicrobium (Meiberg et al., 1980; Barrett and Kwan, 1985). The
other pathway involves an energetically more favorable direct N-
demethylation of trimethylamine to give dimethylamine and formalde-
hyde, catalyzed by trimethylamine dehydrogenase (EC 1.5.8.2) (Colby
and Zatman, 1973) (Fig. 2). In methylotrophs, dimethylamine is further
metabolized to methylamine (MA) and then ammonia, each step
producing formaldehyde, by reactions catalyzed by dimethylamine
dehydrogenase (EC 1.5.8.1) and MA dehydrogenase (amicyanin) (EC
1.4.9.1), respectively (Asatoor and Simenhoff, 1965; Colby and Zatman,
1973; Barrett and Kwan, 1985) (Fig. 2).
Oral and Vaginal Microbiota
The gut, although the major site of TMA production, is not the only
nichewith resident bacterial species capable of producing TMA. Patients
with TMAU report a strange taste in their mouth and may suffer from
bad breath (Mitchell, 2005; Wise et al., 2011). Halitosis is primarily the
result of microbial production of volatile sulfur compounds, short-chain
fatty acids, and diamines (Scully and Greenman, 2012); however, TMA
can also contribute to foul breath odor, either being produced in situ from
choline (Chao and Zeisel, 1990) or as a result of TMA circulatory
overload (Mitchell, 2005). One specific member of the oral microbiota,
Streptococcus sanguis I, has been shown to form TMA from choline,
presumably as a result of enzymatic action on the carbon-nitrogen bond
of choline (Chao and Zeisel, 1990).
In bacterial vaginosis, the vaginal discharge has a prominent fishy
odor owing to elevated amounts of TMA (Brand and Galask, 1986;
Oakley et al., 2008). Vaginal TMA can arise from the degradation of
carnitine and choline or from the reduction of TMAO produced by some
methylotrophs (Barrett and Kwan, 1985) (see previous discussion).
Normally, Lactobacillus and Atopobium spp. are the predominant
members of the vaginal microbiota. In cases of bacterial vaginosis,
Lactobacillus appears to be replaced by genera such as Gardnerella,
Pseudomonas, Mobiluncus, Bacteroides, Prevotella, Porphyromonas,
and Streptococcus (Cruden and Galask, 1988; Hyman et al., 2005;
Armougom and Raoult, 2009). Thus, compared with a healthy vaginal
microbiota, bacterial vaginosis is associated with a higher proportion of
Actinobacteria andBacteroidetes phyla and a lower proportion ofFirmicutes
(Oakley et al., 2008).Mobiluncus strains isolated from patients with bacterial
vaginosis can produce TMA by reduction of TMAO (Cruden and Galask,
1988; Wolrath et al., 2002) and, to a lesser extent, by degradation of choline
(Cruden and Galask, 1988). One Bacteroides isolate has also been shown to
produce TMA from choline (Cruden and Galask, 1988).
As described already, methylotrophs can produce MA, their main
source of energy, from TMA (Barrett and Kwan, 1985). Thus, excess
production of TMA in the mouth and vagina in halitosis and bacterial
vaginosis, respectively, would provide environments favorable to
methylotrophs. Several methylotrophic strains have been shown to be
present in the microbiota of the human mouth (Anesti et al., 2005).
Fig. 2. Metabolism of TMA by gut bacteria. TMA can be metabolized to TMAO,
which is subsequently converted to dimethylamine (DMA) and formaldehyde.
TMA can be converted by direct N-demethylation to DMA and formaldehyde. In
methylotrophs, DMA can be further converted to MA and then ammonia, each
step producing formaldehyde. Reactions are catalyzed by 1, TMA monooxyge-
nase; 2, trimethylamine-oxide aldolase; 3, trimethylamine dehydrogenase; 4,
dimethylamine dehydrogenase and 5, methylamine dehydrogenase (amicyanin).
Based on Colby and Zatman (1973). Names of enzymes are those currently
recommended by the Enzyme Commission, and some differ from those given in
the original papers.
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Noncommensal Bacteria Able to Produce TMA
In humans, TMA-producing bacteria are not limited to the commensal
flora. Some noncommensal bacteria, including pathogens such as
Aeromonas, Burkholderia, Campylobacter, Salmonella, Shigella and
Vibrio, are able to form TMA (Wood and Keeping, 1944; Lerke et al.,
1965; Kwan and Barrett, 1983; Muramatsu et al., 2013) from TMAO,
carnitine, choline or ergothioneine. Noncommensal bacteria that pro-
duce TMA are shown in Table 2.
TMA/TMAO Host-Microbiome Metabolic Axis in Health and
Disease
TMA is produced from dietary precursors by the action of gut bacteria
and is metabolized to TMAO in the liver by a reaction catalyzed by
FMO3 (Fig. 3A).
Factors Affecting the Production of TMA from Dietary
Precursors. Production of TMA by microbial gut action is dependent
on the type and amount of TMA precursors in the diet, the foodstuffs in
which they are present, and the identity and relative abundance of
bacterial species present in the gut.
A study of healthy male volunteers found that, in each individual,
there were striking differences in the amount of TMA produced from
various dietary precursors (15 mmol) administered orally in pure form,
as judged by urinary analysis of TMA and TMA N-oxide (Zhang et al.,
1999). TMAO was the best source, with almost 80% of the dose being
excreted in urine as TMA or TMA N-oxide, followed by choline (about
60%) and carnitine (about 30%); however, betaine, creatinine and
lecithin, although containing a trimethylamino moiety, elicited no
significant increase in urinary excretion of either TMA or TMAO in any
of the individuals studied. In addition, comparison of the amounts of
TMA released by chemical hydrolysis of foods in vitro with those
obtained from biologic digestion of the foods in vivo revealed that
marine fish and seafood are by far the best source of dietary-derived
TMA, with up to 85% of the TMA content of the food being liberated by
biologic digestion. In contrast, red meat, despite its high content of
carnitine, a good source of TMA when ingested in its pure form, is a
relatively poor source of TMA, with only 5% and 12% of the TMA
content of lamb and beef, respectively, being released by biologic
digestion (Zhang et al., 1999; Mitchell et al., 2002). These studies,
although on a relatively small number of individuals, indicate that
amounts of TMA derived from digestion of a particular food cannot be
accurately predicted on the basis of the content of the trimethylamino
moiety in the food.
The human gut microbiome displays considerable interindividual and
intraindividual variation (Caporaso et al., 2011; Yatsunenko et al.,
2012). Such variation would be expected to influence the relative yield
of TMA produced from various foodstuffs. The identity and relative
abundance of gut microbes can be investigated by bacterial cultivation;
however, this approach is limited by the inability to culture some
members of the microbiota (Zoetendal et al., 2008). Although sequence
determination of 16S rDNA is able to identify most major phyla, it is
thought to underestimate Actinobacteria (Tottey et al., 2013), which are
known to produce TMA from TMAO and choline (Table 1). The
development of next-generation deep-sequencing methods will provide
more accurate knowledge of the identity and relative abundance of
bacterial species present in the human gut.
In addition to the identification of bacteria, it is necessary to establish
their functionwith respect to their ability to produce or metabolize TMA.
There are several pathways resulting in the formation of TMA (Fig. 1),
and production of TMA is not exclusive to any one bacterial phylum.
Current taxonomic classification is based on DNA sequence rather
than on bacterial function. Thus, it is possible for a bacterial species
TABLE 2
Noncommensal bacteria that produce trimethylamine (TMA) from various substrates
Phylum Genus or Species References
TMA N-oxide
Bacteroidetes Flavobacterium Robinson et al., 1952
Proteobacteria Achromobacter Campbell and Williams, 1951; Lerke et al., 1965
Aeromonas Lerke et al., 1965; Lin and Hurng, 1989
Alteromonas Lerke et al., 1965; Lee et al., 1977; Easter et al., 1982, 1983;
Ringø et al., 1984
Photobacterium Dalgaard, 1995
Rhodopseudomonas Madigan and Gest, 1979; Cox et al., 1980; Madigan et al., 1980
Salmonella Kwan and Barrett, 1983
Shewanellaa Dalgaard, 1995; López-Caballero et al., 2001; Shaw and Shewan, 1968)
Shigella Wood et al., 1943; Campbell and Williams, 1951
Vibrio Lerke et al., 1965; Unemoto et al., 1965; Shaw and Shewan, 1968;
Easter et al., 1982
Betaine
Firmicutes Haloanaerobacter Mouné et al., 1999
Proteobacteria Desulfuromonas Heijthuijsen and Hansen, 1989
Carnitine
Proteobacteria Achromobacter Zhu et al., 2014
Serratia Unemoto et al., 1966
Shigella Zhu et al., 2014
Choline
Proteobacteria Achromobacter Campbell and Williams, 1951
Shigella Wood and Keeping, 1944
Ergothioneine
Proteobacteria Burkholderia Muramatsu et al., 2013
Campylobacter Muramatsu et al., 2013
Stigmatella Muramatsu et al., 2013
Sinorhizobiumb Muramatsu et al., 2013
aBasionym: Alteromonas putrefaciens.
bBasionym: Rhizobium meliloti.
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belonging to one phylum to share metabolic activity with species
belonging to other phyla but not with other members of the same
phylum. Based on DNA sequence analysis, Bacteroidetes lack the cutC
and cntAB genes (Craciun and Balskus, 2012; Zhu et al., 2014) and, thus,
would appear unlikely to produce TMA from choline or carnitine;
however, in vivo cultivation studies show that some members of the
Bacteroidetes phylum are able to produce TMA from choline (Cruden
and Galask, 1988). In addition, not all strains that encode CutC are able
to produce TMA from choline, and even within the same species, strains
may differ in the ability to convert choline to TMA (Romano et al.,
2015). Thus, one should be cautious when using phylogeny as the sole
predictor of microbial TMA production or as an indicator of metabolic
capacity in general.
The lack of any increase in urinary TMA or TMAO, in response to
ingestion of betaine, in any of the individuals studied (Zhang et al., 1999;
Mitchell et al., 2002) (see preceding) indicates that the metabolic
reactions that produce TMA from betaine, either directly or via
dimethylglycine (Fig. 1), or the bacteria in which these reactions occur,
are not prevalent, at least in healthyBritishmen. The inability to generate
TMA from betaine also indicates that the potential routes for production
of TMA from choline or carnitine, via their initial conversion to betaine
(Fig. 1), do not make significant contributions to TMA production.
Factors affecting the production of TMA in the gut are summarized in
Fig. 3B.
Factors Influencing TMA Metabolism in the Host. Individuals
who consume a ‘typical’ Western diet will produce, via the action of
gut bacteria, about 50 mg of TMA/day (Walker and Wevers, 2012),
most of which (;95%) is converted to TMAO, which is excreted in
the urine (Mitchell and Smith, 2001). Thus, FMO3 is efficient in
dealing with a relatively high substrate load; however, even
individuals with good FMO3 catalytic capacity can become over-
loaded when challenged with large amounts of TMA precursors (Al-
Waiz et al., 1989; Mitchell and Smith, 2016). Dietary components
such as indoles, found in members of the Cruciferare family of
vegetables, have been shown to inhibit the activity of FMO3 in vitro
and, in a human study, to decrease the amount of TMAO produced as
a percentage of total TMA (TMA + TMAO) excreted (Cashman
et al., 1999).
Gender-specific effects in humans also influence the amount of
urinary TMA. In a study of men over a 30-day period, only a slight
variation in the amount of TMA excreted in the urine was seen when
expressed as a percentage of total TMA (TMA + TMAO) (Mitchell and
Smith, 2010). In contrast, women excreted increased urinary TMA
around the time of menstruation, and this increase lasted for ;7 days
(Mitchell and Smith, 2010). This increase in TMA excretion is the result
of a reduction in its metabolism to TMAO, which is thought to be due to
the action of female sex hormones decreasing the expression of the
FMO3 gene (Coecke et al., 1998). In men, high levels of testosterone
also have been found to reduce FMO3 capacity (Ayesh et al., 1995).
Primary TMAU is known to be due to mutations that result in
impaired catalytic activity of FMO3 and, hence, increased urinary
excretion of TMA; however, other situations also cause an increase in
TMA excretion (Mitchell and Smith, 2016), for example, impaired liver
function (Mitchell et al., 1999), impaired renal function (Bain et al.,
2006; Hur et al., 2012; Hao et al., 2013), and pancreatic cancer
(Navaneethan et al., 2014).
Fig. 3. The origin of TMA and TMAO and factors that
influence their production. (A) The production and metabolic
fate of TMA. TMA is produced from dietary precursors by
the action of gut bacteria. TMA can be metabolized by gut
bacteria to TMAO and dimethylamine (DMA) (see Fig. 2) or
absorbed and converted in the liver to TMAO in a reaction
catalyzed by FMO3. TMAO and any unmetabolized TMA
will enter the plasma and subsequently will be excreted in
urine. (B) Factors affecting the production of TMA in the gut.
The amount of TMA produced is dependent on the nature and
quantity of dietary precursors and the relative abundance of
TMA-producing and TMA-metabolizing bacteria. (C) Factors
influencing TMA metabolism in the host. The metabolism of
TMA to TMAO in liver is dependent on the amount and
activity of FMO3. The abundance and activity of FMO3 can
be increased as a consequence of genetic variation, resulting
in an increase in the ratio of TMAO:TMA. The amount and
activity of FMO3 can be decreased by genetic variation,
hormones, inhibitors, and disease, resulting in a decrease in
the ratio of TMAO:TMA.
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The expression of the FMO3 gene in human liver is switched on
between birth and 2 years of age and increases during childhood and
adolescence, reaching its maximum level in adults (Koukouritaki et al.,
2002). Thus, in comparison with adults, children, especially infants,
have lower amounts of FMO3. Consequently, they are less able to
metabolize TMA to TMAO and, thus, may exhibit symptoms of
transient childhood TMAU, particularly if they are homozygous
for two common polymorphic variants of FMO3, c.472G.A [p.
(Glu158Lys)], and c.923A.G [p.(Glu308Gly)], which moderately
reduce catalytic activity (Zschocke and Mayatepek, 2000). One poly-
morphic variant of FMO3, c.1079T . C [p.(Leu360Pro)], increases
catalytic activity (Lattard et al., 2003); however, the variant has been
detected only in African populations and then at low frequency.
Polymorphic promoter-region variants of the FMO3 gene have been
identified that severely reduce transcription in vitro, whereas others
increase transcription (Koukouritaki et al., 2005), but the impact of these
variants on expression of FMO3 in vivo has not been validated. Factors
influencing the metabolism of TMA to TMAO in the liver are
summarized in Fig. 3C.
Potential Involvement of TMAO and FMO3 in Disease. Recently,
TMAO has been implicated in a number of disease states as a cause,
consequence, or biomarker of the disease. It has been suggested that an
increase in the plasma concentration of TMAO, as a consequence of
production of TMA from dietary supplements of choline, carnitine, or
TMAO by gut bacteria and its subsequent oxygenation by FMO3 in the
liver, increases the risk of cardiovascular disease (Wang et al., 2011;
Bennett et al., 2013; Koeth et al., 2013; Tang et al., 2013; Obeid et al.,
2016). TMAO has also been implicated in chronic kidney disease (Tang
et al., 2015), colorectal cancer (Xu et al., 2015), and in impaired glucose
tolerance inmice fed a high-fat diet and a TMAO supplement (Gao et al.,
2014); however, lower plasma concentrations of TMAO have been
associated with inflammatory bowel disease and with active versus
inactive ulcerative colitis (Wilson et al., 2015).
A number of roles for FMO3 itself in health and disease have been
suggested, based on studies using mice. Knockdown of FMO3 mRNA
by antisense oligonucleotides in female low-density lipoprotein
receptor-knockout mice suggests a role for FMO3 inmodulating glucose
and lipid homeostasis (Shih et al., 2015). FMO3 has also been identified
as a target of insulin (Miao et al., 2015): Fmo3 expression wasmore than
1000-fold higher in the livers of male liver insulin receptor-knockout
(LIRKO) mice compared with littermate controls, whereas knockdown
of FMO3 in LIRKO mice reduced expression of the transcription factor
forkhead box O1 and prevented the development of hyperglycemia,
hyperlipidemia, and atherosclerosis. Other suggested roles for FMO3
include involvement in cholesterol metabolism and reverse cholesterol
transport (Bennett et al., 2013; Warrier et al., 2015).
The implication that TMAO itself is a causative factor for cardiovas-
cular and other diseases is controversial. A recent review considers in
detail the physiologic roles of TMAO and the evidence for and against
TMAO being detrimental for health (Ufnal et al., 2015). The link
between TMAO levels and atherosclerosis seems counterintuitive
considering that consumption of marine fish, the richest dietary source
of TMAO (Zhang et al., 1999), is firmly associated with a reduction in
the incidence of cardiovascular disease (Takata et al., 2013). Other
studies found no correlation of TMAO levels with biomarkers of
cardiovascular disease. For instance, elevated levels of TMAO caused
no increase in C-reactive protein or low-density lipoprotein, in either
mouse or human plasma (Miller et al., 2014), and a study of oral
carnitine supplementation of patients undergoing hemodialysis showed
that, although TMAO was increased, markers of vascular injury were
reduced, and, consequently, supplementation with carnitine is thought to
be beneficial for these patients (Fukami et al., 2015). Indeed, carnitine
has proven efficacious for treatment of cardiovascular disease (Flanagan
et al., 2010).
Many of the studies that implicate TMAO as a causative factor in
cardiovascular disease are based on studies of mice and involve chronic
administration of pure TMA precursors in amounts that far exceed those
present either in a normal diet or in therapeutic supplements. Indeed, in
the case of carnitine, significant increases in dietary-derived TMA in
humans are obtained only with high chronic dose regimens (Holmes
et al., 1997). Consequently, normal dietary conditions or moderate
supplementation are unlikely to elicit the production of the amounts of
TMAO that have been associated with cardiovascular disease.
When designing experimental studies on mice and extrapolating the
results of these experiments to humans, it is important to appreciate that
there is a species-specific gender difference in the expression of FMO3
between humans and mice. At about 6 weeks of age, expression of the
Fmo3 gene is switched off in the liver of male, but not of female, mice
(Falls et al., 1995; Janmohamed et al., 2004). After this age, male mice
produce no hepatic FMO3 protein; thus, in comparison with female
mice, produce far less TMAO and, consequently, excrete larger amounts
of TMA in their urine. Despite this marked gender-specific difference,
there is no obvious difference in the propensity of male and female wild-
type mice to develop cardiovascular disease. A study of adult C57BL/6
wild-type mice found no difference in plasma glucose between male and
female mice and showed that females, which express hepatic FMO3 and
thus produce TMAO, have lower plasma cholesterol than males
(Gonzalez Malagon et al., 2015). A further complication is that humans
do not express FMO1 in liver (Dolphin et al., 1991; Phillips et al., 1995;
Koukouritaki et al., 2002), in marked contrast to all other mammals
investigated, in which FMO1 is a major form of FMO in this tissue
(Hernandez et al., 2004).
Evidence has shown that the FMO3 gene of humans has been the
subject of balancing natural selection (Allerston et al., 2007). Three
alleles appear to be targets for selection: the ancestral allele, an allele
encoding an enzyme with moderately reduced catalytic activity, and one
associated with increased promoter activity. Heterozygotes for a loss-of-
function mutation of FMO3, despite having a 50% reduction of FMO3
activity, are able to convert ;95% of a normal dietary load of TMA to
TMAO and, in this respect, are indistinguishable from individuals
homozygous for a functional FMO3 gene (Al-Waiz et al., 1987c). This
finding indicates that it is unlikely that the decreased capacity to produce
TMAO was the evolutionary advantage that drove selection of the allele
encoding a FMO3 with reduced activity.
An alternative explanation for high levels of TMAO associated with
cardiovascular disease is that the concentrations are indicative of
dysfunction(s) elsewhere and that TMAO is not the mediator but is
merely a marker of the disease (Ufnal et al., 2015). In mice, TMAO
increases in response to a high-fat diet (Yang et al., 2014). High-fat diets
change the composition of the gut microbiome to one associated with
obesity and its related health problems. These changes increase the
relative proportion of Firmicutes (Ley et al., 2006), a phylum whose
members contribute to TMA production, and decrease that of Bacter-
iodetes, a phylum that contributes very little to TMA production
(Table 1). Elevated plasma and urinary TMAO, therefore, may be a
marker for a gut microbiome that has deleterious effects on health and
not itself a causative factor. Indeed, atherosclerosis indices were
increased in mice in response to a high-fat diet, but dietary supplemen-
tation with TMAO had the opposite effect, significantly decreasing
atherosclerosis indices (Gao et al., 2014). It is important to note that no
health benefits have been reported for TMAU individuals, who produce
very low amounts of TMAO because of their impaired FMO3 activity.
Implications for TMAU. One disorder known unambiguously to be
associated with FMO3 is primary TMAU, caused by mutations in the
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FMO3 gene (Dolphin et al., 1997) (see previous discussion), a condition
characterized by secretion of excessive amounts of odorous TMA
(Mitchell and Smith, 2001). There is no cure for the disorder, and current
treatment is aimed at management of the symptoms. The main approach
is restriction of dietary precursors of TMA. Although humans may
possess gut bacteria capable of producing TMA from choline and
carnitine when administered in pure form, they are much less able to
access these precursors from foodstuffs such as red meat and peanuts
(Zhang et al., 1999; Mitchell et al., 2002). In contrast, the precursor
TMAO is efficiently extracted in the gut from marine fish and seafood
(Zhang et al., 1999; Mitchell et al., 2002). These results have
implications for dietary management of TMAU, indicating that the
most important foodstuffs to avoid are marine fish and seafood and those
that contain free choline, such as soya bean-derived milk, whereas red
meat would contribute less to TMA load.
Another strategy would be manipulation of gut flora to reduce the
proportion of bacteria that produce TMA and increase the proportion of
those that metabolize TMA. Although TMA-producing species are
widely distributed across bacterial phyla, they are more common in
Firmicutes and relatively scarce in Bacteriodetes (Table 1). Conse-
quently, decreasing the ratio of Firmicutes to Bacteriodetes would be
expected to reduce production of TMA from dietary precursors. A low
ratio of Firmicutes to Bacteriodetes is associated with a healthy
microbiome (Ley et al., 2006); thus, such alteration of the gut micro-
biome would promote general health as well as aiding in the manage-
ment of TMAU.
One approach to altering the composition of the gut microbiome is
exogenous supplementation with beneficial species (probiotics); how-
ever, a recent study found that the multistrain probiotic VSL#3 had no
effect on the increase in plasma concentration of TMAO in individuals
fed a high-fat diet (Boutagy et al., 2015). Another proposal is the
therapeutic use of methylotrophic strains of archaea (archaebiotics) that
use TMA as an energy source (Brugère et al., 2014), although this has
yet to be tried.
A further possibility is the selective inhibition of bacterial enzymes
that catalyze reactions involved in the production of TMA. Candidates
are TMA reductase, CutC, and CntAB, which respectively catalyze
TMA production from TMAO, choline and carnitine (Fig. 1). For
instance, 3,3-dimethyl-1-butanol, a structural analog of choline, inhibits
microbial CutC and reduces the plasma concentration of TMAO in mice
fed diets rich in choline or carnitine (Wang et al., 2015); however, most
of the choline eaten by humans is in the form of lecithin, which is not a
good dietary source of TMA (Zhang et al., 1999); thus, the efficacy of
the inhibitor for reducing TMA production in human gut is unclear.
Conclusions
TMA is derived from dietary precursors via the action of gut
bacteria. The amount of TMA absorbed by humans is determined by
the type and quantity of dietary precursors and the composition of the
gut microbiome, in particular with respect to bacteria that produce or
consume TMA. TMAO, choline, and carnitine, but not betaine,
creatinine, and lecithin, are good sources of TMA in their pure form.
Marine fish and seafood are the best food sources of TMA, but red
meat, despite its high content of carnitine, is a poor source.
Consequently, it is not possible to predict the amount of TMA that
will be derived from a particular food on the basis of the content of the
trimethylamino moiety in the food. Bacteria from several phyla
produce TMA from dietary precursors but are more common in
Firmicutes and scarce in Bacteriodetes.
FMO3, its microbiome-derived substrate TMA and the product of
FMO3 catalysis, TMAO, have been implicated in a number of disease
states. That mutations of FMO3 cause the inherited disorder primary
TMAU, through a failure to convert TMA to TMAO, is well established;
however, TMAO has attracted increasing notoriety as a molecule that
might be harmful for health. The evidence for this is controversial, and
there are studies for and against the importance of TMAO in conditions
affecting health. No known health benefits have been reported as a
consequence of the lack or low production of TMAO in primary TMAU
patients. Large, well-designed clinical studies are needed to examine
whether changes in the plasma concentration of TMAO in non-TMAU
patients are a consequence of the diet of an individual or of the bacterial
species that populate their gut, which may well change in response to the
health status of an individual. It is intriguing that consumption of marine
fish, the richest dietary source of TMAO, is beneficial, not harmful, to
cardiovascular health.
In addition, FMO3 has a wide range of drug substrates. This, together
with its intimate relationship with the microbiome-produced FMO3
substrate TMA, indicates that changes in composition of the gut
microbiome might influence both the metabolism and efficacy of
therapeutic drugs.
Authorship Contributions
Contributed to the writing of the manuscript: Fennema, Phillips, Shephard.
References
Al-Waiz M, Ayesh R, Mitchell SC, Idle JR, and Smith RL (1987c) A genetic polymorphism of the
N-oxidation of trimethylamine in humans. Clin Pharmacol Ther 42:588–594.
Al-Waiz M, Ayesh R, Mitchell SC, Idle JR, and Smith RL (1989) Trimethylaminuria: the detection
of carriers using a trimethylamine load test. J Inherit Metab Dis 12:80–85.
Al-Waiz M, Mikov M, Mitchell SC, and Smith RL (1992) The exogenous origin of trimethylamine
in the mouse. Metabolism 41:135–136.
Al-Waiz M, Mitchell SC, Idle JR, and Smith RL (1987a) The metabolism of 14C-labelled tri-
methylamine and its N-oxide in man. Xenobiotica 17:551–558.
Al-Waiz M, Mitchell SC, Idle JR, and Smith RL (1987b) The relative importance of N-oxidation
and N-demethylation in the metabolism of trimethylamine in man. Toxicology 43:117–121.
Allerston CK, Shimizu M, Fujieda M, Shephard EA, Yamazaki H, and Phillips IR (2007) Mo-
lecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene
(FMO3). Pharmacogenet Genomics 17:827–839.
Andresen PA, Kaasen I, Styrvold OB, Boulnois G, and Strøm AR (1988) Molecular cloning,
physical mapping and expression of the bet genes governing the osmoregulatory choline-glycine
betaine pathway of Escherichia coli. J Gen Microbiol 134:1737–1746.
Anesti V, McDonald IR, Ramaswamy M, Wade WG, Kelly DP, and Wood AP (2005) Isolation
and molecular detection of methylotrophic bacteria occurring in the human mouth. Environ
Microbiol 7:1227–1238.
Armougom F and Raoult D (2009) Exploring microbial diversity using 16S rRNA high-throughput
methods. J Comput Sci Syst Biol 2:74–92.
Asatoor AM and Simenhoff ML (1965) The origin of urinary dimethylamine. Biochim Biophys
Acta 111:384–392.
Ayesh R, Mitchell SC, and Smith RL (1995) Dysfunctional N-oxidation of trimethylamine and the
influence of testosterone treatment in man. Pharmacogenetics 5:244–246.
Ayesh R, Mitchell SC, Zhang A, and Smith RL (1993) The fish odour syndrome: biochemical,
familial, and clinical aspects. BMJ 307:655–657.
Bain MA, Faull R, Fornasini G, Milne RW, and Evans AM (2006) Accumulation of trimethyl-
amine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis.
Nephrol Dial Transplant 21:1300–1304.
Baker FD, Papiska HR, and Campbell LL (1962) Choline fermentation by Desulfovibrio desul-
furicans. J Bacteriol 84:973–978.
Barrett EL and Kwan HS (1985) Bacterial reduction of trimethylamine oxide. Annu Rev Microbiol
39:131–149.
Beatty SA (1938) Studies of Fish Spoilage: II. The origin of trimethylamine produced during the
spoilage of cod muscle press juice. J Fish Res Bd Can 4a:63–68.
Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, Allayee H, Lee R,
Graham M, Crooke R, et al. (2013) Trimethylamine-N-oxide, a metabolite associated with
atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 17:49–60.
Boulton CA, Crabbe MJ, and Large PJ (1974) Microbial oxidation of amines. Partial purification of
a trimethylamine mono-oxygenase from Pseudomonas aminovorans and its role in growth on
trimethylamine. Biochem J 140:253–263.
Boutagy NE, Neilson AP, Osterberg KL, Smithson AT, Englund TR, Davy BM, Hulver MW,
and Davy KP (2015) Probiotic supplementation and trimethylamine-N-oxide production fol-
lowing a high-fat diet. Obesity (Silver Spring) 23:2357–2363.
Bradbeer C (1965) The clostridial fermentations of choline and ethanolamine. 1. Preparation and
properties of cell-free extracts. J Biol Chem 240:4669–4674.
Brand JM and Galask RP (1986) Trimethylamine: the substance mainly responsible for the fishy
odor often associated with bacterial vaginosis. Obstet Gynecol 68:682–685.
Brugère J-F, Borrel G, Gaci N, Tottey W, O’Toole PW, and Malpuech-Brugère C (2014) Arch-
aebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular
disease. Gut Microbes 5:5–10.
Campbell LL, Jr and Williams OB (1951) The action of members of the genus Achromobacter on
trimethylamine oxide and related compounds. J Bacteriol 62:249–251.
TMA/TMAO, an FMO3-Mediated Host-Microbiome Metabolic Axis 1847
 at A









Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, Knights D,
Gajer P, Ravel J, Fierer N, et al. (2011) Moving pictures of the human microbiome. Genome Biol
12:R50.
Cashman JR (2008) Role of flavin-containing monooxygenase in drug development. Expert Opin
Drug Metab Toxicol 4:1507–1521.
Cashman JR, Park SB, Berkman CE, and Cashman LE (1995) Role of hepatic flavin-containing
monooxygenase 3 in drug and chemical metabolism in adult humans. Chem Biol Interact 96:
33–46.
Cashman JR, Xiong Y, Lin J, Verhagen H, van Poppel G, van Bladeren PJ, Larsen-Su S,
and Williams DE (1999) In vitro and in vivo inhibition of human flavin-containing mono-
oxygenase form 3 (FMO3) in the presence of dietary indoles. Biochem Pharmacol 58:
1047–1055.
Caspi R, Altman T, Billington R, Dreher K, Foerster H, Fulcher CA, Holland TA, Keseler IM,
Kothari A, Kubo A, et al. (2014) The MetaCyc database of metabolic pathways and enzymes and
the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res 42:D459–D471.
Chalmers RA, Bain MD, Michelakakis H, Zschocke J, and Iles RA (2006) Diagnosis and man-
agement of trimethylaminuria (FMO3 deficiency) in children. J Inherit Metab Dis 29:162–172.
Chao CK and Zeisel SH (1990) Formation of trimethylamine from dietary choline by Streptococcus
sanguis I, which colonizes the mouth. J Nutr Biochem 1:89–97.
Cheah IK and Halliwell B (2012) Ergothioneine; antioxidant potential, physiological function and
role in disease. Biochim Biophys Acta 1822:784–793.
Chen Y, Patel NA, Crombie A, Scrivens JH, and Murrell JC (2011) Bacterial flavin-containing
monooxygenase is trimethylamine monooxygenase. Proc Natl Acad Sci USA 108:17791–17796.
Coecke S, Debast G, Phillips IR, Vercruysse A, Shephard EAE, and Rogiers V (1998) Hormonal
regulation of microsomal flavin-containing monooxygenase activity by sex steroids and growth
hormone in co-cultured adult male rat hepatocytes. Biochem Pharmacol 56:1047–1051.
Colby J and Zatman LJ (1973) Trimethylamine metabolism in obligate and facultative methylo-
trophs. Biochem J 132:101–112.
Cox JC and Knight R (1981) Trimethylamine N-oxide (TMAO) reductase activity in chlorate-
resistant or respiration-deficient mutants of Escherichia coli. FEMS Microbiol Lett 12:249–252.
Cox JC, Madigan MT, Favinger JL, and Gest H (1980) Redox mechanisms in “oxidant-dependent”
hexose fermentation by Rhodopseudomonas capsulata. Arch Biochem Biophys 204:10–17.
Craciun S and Balskus EP (2012) Microbial conversion of choline to trimethylamine requires a
glycyl radical enzyme. Proc Natl Acad Sci USA 109:21307–21312.
Cruciani G, Valeri A, Goracci L, Pellegrino RM, Buonerba F, and Baroni M (2014) Flavin
monooxygenase metabolism: why medicinal chemists should matter. J Med Chem 57:
6183–6196.
Cruden DL and Galask RP (1988) Reduction of trimethylamine oxide to trimethylamine by
Mobiluncus strains isolated from patients with bacterial vaginosis. Microb Ecol Health Dis 1:
95–100.
Dalgaard P (1995) Qualitative and quantitative characterization of spoilage bacteria from packed
fish. Int J Food Microbiol 26:319–333.
Denby KJ, Rolfe MD, Crick E, Sanguinetti G, Poole RK, and Green J (2015) Adaptation of
anaerobic cultures of Escherichia coli K-12 in response to environmental trimethylamine-N-
oxide. Environ Microbiol 17:2477–2491.
Ditullio D, Anderson D, Chen CS, and Sih CJ (1994) L-carnitine via enzyme-catalyzed oxidative
kinetic resolution. Bioorg Med Chem 2:415–420.
Dolphin C, Shephard EA, Povey S, Palmer CN, Ziegler DM, Ayesh R, Smith RL, and Phillips IR
(1991) Cloning, primary sequence, and chromosomal mapping of a human flavin-containing
monooxygenase (FMO1). J Biol Chem 266:12379–12385.
Dolphin CT, Cullingford TE, Shephard EA, Smith RL, and Phillips IR (1996) Differential de-
velopmental and tissue-specific regulation of expression of the genes encoding three members of
the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04. Eur J Biochem
235:683–689.
Dolphin CT, Janmohamed A, Smith RL, Shephard EA, and Phillips IR (1997) Missense mutation
in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat Genet
17:491–494.
Dolphin CT, Janmohamed A, Smith RL, Shephard EA, and Phillips IR (2000) Compound het-
erozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in
patients with fish-odour syndrome. Pharmacogenetics 10:799–807.
Easter MC, Gibson DM, and Ward FB (1982) A conductance method for the assay and study of
bacterial trimethylamine oxide reduction. J Appl Bacteriol 52:357–365.
Easter MC, Gibson DM, and Ward FB (1983) The induction and location of trimethylamine-N-
oxide reductase in Alteromonas sp. NCMB 400. Microbiology 129:3689–3696.
Eddy BP (1953) Bacterial degradation of choline. Nature 171:573–574.
Ey J, Schömig E, and Taubert D (2007) Dietary sources and antioxidant effects of ergothioneine.
J Agric Food Chem 55:6466–6474.
Falls JG, Blake BL, Cao Y, Levi PE, and Hodgson E (1995) Gender differences in hepatic
expression of flavin-containing monooxygenase isoforms (FMO1, FMO3, and FMO5) in mice.
J Biochem Toxicol 10:171–177.
Feller AG and Rudman D (1988) Role of carnitine in human nutrition. J Nutr 118:541–547.
Fiebig K and Gottschalk G (1983) Methanogenesis from choline by a coculture of Desulfovibrio sp.
and Methanosarcina barkeri. Appl Environ Microbiol 45:161–168.
Flanagan JL, Simmons PA, Vehige J, Willcox MD, and Garrett Q (2010) Role of carnitine in
disease. Nutr Metab (Lond) 7:30.
Fukami K, Yamagishi S, Sakai K, Kaida Y, Yokoro M, Ueda S, Wada Y, Takeuchi M, Shimizu M,
Yamazaki H, et al. (2015) Oral L-carnitine supplementation increases trimethylamine-N-oxide
but reduces markers of vascular injury in hemodialysis patients. J Cardiovasc Pharmacol 65:
289–295.
Gao X, Liu X, Xu J, Xue C, Xue Y, and Wang Y (2014) Dietary trimethylamine N-oxide
exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng 118:476–481.
Gonzalez Malagon SG, Melidoni AN, Hernandez D, Omar BA, Houseman L, Veeravalli S, Scott F,
Varshavi D, Everett J, Tsuchiya Y, et al. (2015) The phenotype of a knockout mouse identifies
flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing. Biochem
Pharmacol 96:267–277.
Gut I and Conney AH (1991) The FAD-containing monooxygenase-catalyzed N-oxidation and
demethylation of trimethylamine in rat liver microsomes. Drug Metabol Drug Interact 9:
201–208.
Gut I and Conney AH (1993) Trimethylamine N-oxygenation and N-demethylation in rat liver
microsomes. Biochem Pharmacol 46:239–244.
Hao X, Liu X, Wang W, Ren H, Xie J, Shen P, Lin D, and Chen N (2013) Distinct metabolic
profile of primary focal segmental glomerulosclerosis revealed by NMR-based metabolomics.
PLoS One 8:e78531.
Hayward HR and Stadtman TC (1959) Anaerobic degradation of choline. I. Fermentation of
choline by an anaerobic, cytochrome-producing bacterium, Vibrio cholinicus n. sp. J Bacteriol
78:557–561.
Hayward HR and Stadtman TC (1960) Anaerobic degradation of choline. II. Preparation and
properties of cell-free extracts of Vibrio cholinicus. J Biol Chem 235:538–543.
Heijthuijsen JH and Hansen TA (1989) Betaine fermentation and oxidation by marine desulfur-
omonas strains. Appl Environ Microbiol 55:965–969.
Hernandez D, Addou S, Lee D, Orengo C, Shephard EA, and Phillips IR (2003) Trimethylaminuria
and a human FMO3 mutation database. Hum Mutat 22:209–213.
Hernandez D, Janmohamed A, Chandan P, Phillips IR, and Shephard EA (2004) Organization and
evolution of the flavin-containing monooxygenase genes of human and mouse: identification of
novel gene and pseudogene clusters. Pharmacogenetics 14:117–130.
Higgins T, Chaykin S, Hammond KB, and Humbert JR (1972) Trimethylamine N-oxide synthesis:
a human variant. Biochem Med 6:392–396.
Hirsch MJ, Growdon JH, and Wurtman RJ (1978) Relations between dietary choline or lecithin
intake, serum choline levels, and various metabolic indices. Metabolism 27:953–960.
Holmes HC, Burns SP, Michelakakis H, Kordoni V, Bain MD, Chalmers RA, Rafter JE, and Iles
RA (1997) Choline and L-carnitine as precursors of trimethylamine. Biochem Soc Trans 25:96S.
Hormann K and Andreesen JR (1989) Reductive cleavage of sarcosine and betaine by Eubacterium
acidaminophilum via enzyme systems different from glycine reductase. Arch Microbiol 153:
50–59.
Hur E, Gungor O, Bozkurt D, Bozgul S, Dusunur F, Caliskan H, Berdeli A, Akcicek F, Basci A,
and Duman S (2012) Trimethylaminuria (fish malodour syndrome) in chronic renal failure.
Hippokratia 16:83–85.
Hyman RW, Fukushima M, Diamond L, Kumm J, Giudice LC, and Davis RW (2005) Microbes on
the human vaginal epithelium. Proc Natl Acad Sci USA 102:7952–7957.
Ishimoto M and Shimokawa O (1978) Reduction of trimethylamine N-oxide by Escherichia coli as
anaerobic respiration. Z Allg Mikrobiol 18:173–181.
Janmohamed A, Dolphin CT, Phillips IR, and Shephard EA (2001) Quantification and cellular
localization of expression in human skin of genes encoding flavin-containing monooxygenases
and cytochromes P450. Biochem Pharmacol 62:777–786.
Janmohamed A, Hernandez D, Phillips IR, and Shephard EA (2004) Cell-, tissue-, sex- and
developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos).
Biochem Pharmacol 68:73–83.
Kalnins G, Kuka J, Grinberga S, Makrecka-Kuka M, Liepinsh E, Dambrova M, and Tars K (2015)
Structure and fubction of CutC choline lyase from human microbiota bacterium Klebsiella
pneumonia. J Biol Chem 290:21732–21740.
Kelly B and Appleman MD (1961) Degradation of ergothioneine by cell-free extracts of Alcali-
genes faecalis. J Bacteriol 81:715–720.
Kleber H-P (1997) Bacterial carnitine metabolism. FEMS Microbiol Lett 147:1–9.
Kleber H-P, Seim H, Aurich H, and Strack E (1977) [Utilization of trimethylammonium-
compounds by Acinetobacter calcoaceticus (author’s transl)]. Arch Microbiol 112:201–206.
Kleber H-P, Seim H, Aurich H, and Strack E (1978) [Interrelationships between carnitine me-
tabolism and fatty acid assimilation in Pseudomonas putida (author’s transl)]. Arch Microbiol
116:213–220.
Koeth RA, Levison BS, Culley MK, Buffa JA, Wang Z, Gregory JC, Org E, Wu Y, Li L, Smith JD,
et al. (2014) g-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of
L-carnitine to TMAO. Cell Metab 20:799–812.
Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, et al.
(2013) Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes ath-
erosclerosis. Nat Med 19:576–585.
Koukouritaki SB, Poch MT, Cabacungan ET, McCarver DG, and Hines RN (2005) Discovery of
novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and
functional analysis of upstream haplotype variants. Mol Pharmacol 68:383–392.
Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, and Hines RN (2002) Human hepatic flavin-
containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res
51:236–243.
Krueger SK and Williams DE (2005) Mammalian flavin-containing monooxygenases: structur-
e/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 106:357–387.
Kuka J, Liepinsh E, Makrecka-Kuka M, Liepins J, Cirule H, Gustina D, Loza E, Zharkova-
Malkova O, Grinberga S, Pugovics O, et al. (2014) Suppression of intestinal microbiota-
dependent production of pro-atherogenic trimethylamine N-oxide by shifting L-carnitine
microbial degradation. Life Sci 117:84–92.
Kwan HS and Barrett EL (1983) Purification and properties of trimethylamine oxide reductase from
Salmonella typhimurium. J Bacteriol 155:1455–1458.
Lang DH, Yeung CK, Peter RM, Ibarra C, Gasser R, Itagaki K, Philpot RM, and Rettie AE (1998)
Isoform specificity of trimethylamine N-oxygenation by human flavin-containing mono-
oxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem Pharmacol 56:
1005–1012.
Large PJ, Boulton CA, and Crabbe MJ (1972) The reduced nicotinamide-adenine dinucleotide
phosphate- and oxygen-dependent N-oxygenation of trimethylamine by Pseudomonas amino-
vorans. Biochem J 128:137P–138P.
Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, and Cashman JR (2003) Two new polymor-
phisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic
and functional studies. Drug Metab Dispos 31:854–860.
Lee JV, Gibson DM, and Shewan JM (1977) A numerical taxonomic study of some Pseudomonas-
like marine bacteria. J Gen Microbiol 98:439–451.
Lerke P, Adams R, and Farber L (1965) Bacteriology of spoilage of fish muscle. 3. Characterization
of spoilers. Appl Microbiol 13:625–630.
Ley RE, Turnbaugh PJ, Klein S, and Gordon JI (2006) Microbial ecology: human gut microbes
associated with obesity. Nature 444:1022–1023.
Lin JK and Hurng DC (1989) Potentiation of ferrous sulphate and ascorbate on the microbial
transformation of endogenous trimethylamine N-oxide to trimethylamine and dimethylamine in
squid extracts. Food Chem Toxicol 27:613–618.
López-Caballero ME, Sánchez-Fernández JA, and Moral A (2001) Growth and metabolic activity
of Shewanella putrefaciens maintained under different CO2 and O2 concentrations. Int J Food
Microbiol 64:277–287.
1848 Fennema et al.
 at A









Madigan MT and Gest H (1979) Growth of the photosynthetic bacterium Rhodopseudomonas
capsulata chemoautotrophically in darkness with H2 as the energy source. J Bacteriol 137:
524–530.
Madigan MT, Cox JC, and Gest H (1980) Physiology of dark fermentative growth of Rhodop-
seudomonas capsulata. J Bacteriol 142:908–915.
Martínez-del Campo A, Bodea S, Hamer HA, Marks JA, Haiser HJ, Turnbaugh PJ, and Balskus EP
(2015) Characterization and detection of a widely distributed gene cluster that predicts anaerobic
choline utilization by human gut bacteria. MBio 6:e00042–15.
Mayatepek E, Flock B, and Zschocke J (2004) Benzydamine metabolism in vivo is impaired in
patients with deficiency of flavin-containing monooxygenase 3. Pharmacogenetics 14:775–777.
Meadows JA and Wargo MJ (2015) Carnitine in bacterial physiology and metabolism. Microbio-
logy 161:1161–1174.
Meiberg JBM, Bruinenberg PM, and Harder W (1980) Effect of dissolved oxygen tension on the
metabolism of methylated amines in Hyphomicrobium X in the absence and presence of nitrate:
Evidence for “aerobic” denitrification. Microbiol 120:453–463.
Miao J, Ling AV, Manthena PV, Gearing ME, Graham MJ, Crooke RM, Croce KJ, Esquejo RM,
Clish CB, Vicent D, et al.; Morbid Obesity Study Group (2015) Flavin-containing mono-
oxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun 6:6498.
Miller CA, Corbin KD, da Costa K-A, Zhang S, Zhao X, Galanko JA, Blevins T, Bennett BJ,
O’Connor A, and Zeisel SH (2014) Effect of egg ingestion on trimethylamine-N-oxide pro-
duction in humans: a randomized, controlled, dose-response study. Am J Clin Nutr 100:778–786.
Mitchell S, Ayesh R, Barrett T, and Smith R (1999) Trimethylamine and foetor hepaticus. Scand J
Gastroenterol 34:524–528.
Mitchell SC (2005) Trimethylaminuria (fish-odour syndrome) and oral malodour. Oral Dis 11
(Suppl 1):10–13.
Mitchell SC and Smith RL (2001) Trimethylaminuria: the fish malodor syndrome. Drug Metab
Dispos 29:517–521.
Mitchell SC and Smith RL (2010) A physiological role for flavin-containing monooxygenase
(FMO3) in humans? Xenobiotica 40:301–305.
Mitchell SC and Smith RL (2016) Trimethylamine-the extracorporeal envoy. Chem Senses 41:
275–279.
Mitchell SC, Zhang AQ, and Smith RL (2002) Chemical and biological liberation of trimethyl-
amine from foods. J Food Compos Anal 15:277–282.
Miura-Fraboni J, Kleber H-P, and Englard S (1982) Assimilation of g-butyrobetaine, and D-and
L-carnitine by resting cell suspensions of Acinetobacter calcoaceticus and Pseudomonas putida.
Arch Microbiol 133:217–221.
Mouné S, Manac’h N, Hirschler A, Caumette P, Willison JC, and Matheron R (1999) Hal-
oanaerobacter salinarius sp. nov., a novel halophilic fermentative bacterium that reduces
glycine-betaine to trimethylamine with hydrogen or serine as electron donors; emendation of the
genus Haloanaerobacter. Int J Syst Bacteriol 49:103–112.
Möller B, Hippe H, and Gottschalk G (1986) Degradation of various amine compounds by mes-
ophilic clostridia. Arch Microbiol 145:85–90.
Muramatsu H, Matsuo H, Okada N, Ueda M, Yamamoto H, Kato S, and Nagata S (2013) Char-
acterization of ergothionase from Burkholderia sp. HME13 and its application to enzymatic
quantification of ergothioneine. Appl Microbiol Biotechnol 97:5389–5400.
Mushiroda T, Douya R, Takahara E, and Nagata O (2000) The involvement of flavin-
containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a
gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab
Dispos 28:1231–1237.
Myers PA and Zatman LJ (1971) The metabolism of trimethylamine N-oxide by Bacillus PM6.
Biochem J 121:10P.
Naumann E, Hippe H, and Gottschalk G (1983) Betaine: New oxidant in the Stickland reaction and
methanogenesis from betaine and l-alanine by a Clostridium sporogenes-Methanosarcina bar-
keri coculture. Appl Environ Microbiol 45:474–483.
Navaneethan U, Parsi MA, Gutierrez NG, Bhatt A, Venkatesh PGK, Lourdusamy D, Grove D,
Hammel JP, Jang S, Sanaka MR, et al. (2014) Volatile organic compounds in bile can diagnose
malignant biliary strictures in the setting of pancreatic cancer: a preliminary observation. Gas-
trointest Endosc 80:1038–1045.
Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, and Pettersson S (2012) Host-gut
microbiota metabolic interactions. Science 336:1262–1267.
Oakley BB, Fiedler TL, Marrazzo JM, and Fredricks DN (2008) Diversity of human vaginal
bacterial communities and associations with clinically defined bacterial vaginosis. Appl Environ
Microbiol 74:4898–4909.
Obeid R (2013) The metabolic burden of methyl donor deficiency with focus on the betaine
homocysteine methyltransferase pathway. Nutrients 5:3481–3495.
Obeid R, Awwad HM, Rabagny Y, Graeber S, Herrmann W, and Geisel J (2016) Plasma trime-
thylamine N-oxide concentration is associated with choline, phospholipids, and methyl metab-
olism. Am J Clin Nutr 103:703–711.
Pang PKT, Griffith RW, and Atz JW (1977) Osmoregulation in elasmobranchs. Am Zool 17:
365–377.
Parte P and Kupfer D (2005) Oxidation of tamoxifen by human flavin-containing monooxygenase
(FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human
cytochromes P450 and hemoglobin. Drug Metab Dispos 33:1446–1452.
Pfeiffer C, Bauer T, Surek B, Schömig E, and Gründemann D (2011) Cyanobacteria produce high
levels of ergothioneine. Food Chem 129:1766–1769.
Phillips IR, Dolphin CT, Clair P, Hadley MR, Hutt AJ, McCombie RR, Smith RL, and Shephard
EA (1995) The molecular biology of the flavin-containing monooxygenases of man. Chem Biol
Interact 96:17–32.
Phillips IR, Francois AA, and Shephard EA (2007) The flavin-containing monooxygenases
(FMOs): genetic variation and its consequences for the metabolism of therapeutic drugs. Curr
Pharmacogenomics 5:292–313.
Phillips IR and Shephard EA (2008) Flavin-containing monooxygenases: mutations, disease and
drug response. Trends Pharmacol Sci 29:294–301.
Rebouche CJ and Chenard CA (1991) Metabolic fate of dietary carnitine in human adults: iden-
tification and quantification of urinary and fecal metabolites. J Nutr 121:539–546.
Rebouche CJ and Seim H (1998) Carnitine metabolism and its regulation in microorganisms and
mammals. Annu Rev Nutr 18:39–61.
Ringø E, Stenberg E, and Strøm AR (1984) Amino acid and lactate catabolism in trimethylamine
oxide respiration of Alteromonas putrefaciens NCMB 1735. Appl Environ Microbiol 47:
1084–1089.
Robinson J, Gibbons NE, and Thatcher FS (1952) A mechanism of halophilism in Micrococcus
halodenitrificans. J Bacteriol 64:69–77.
Romano KA, Vivas EI, Amador-Noguez D, and Rey FE (2015) Intestinal microbiota composition
modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite
trimethylamine-N-oxide. MBio 6:e02481.
Scully C and Greenman J (2012) Halitology (breath odour: aetiopathogenesis and management).
Oral Dis 18:333–345.
Seebeck FP (2010) In vitro reconstitution of Mycobacterial ergothioneine biosynthesis. J Am Chem
Soc 132:6632–6633.
Seim H, Löster H, Claus R, Kleber H-P, and Strack E (1982a) Formation of g-butyrobetaine and
trimethylamine from quaternary ammonium compounds structure-related to L-carnitine and
choline by Proteus vulgaris. FEMS Microbiol Lett 13:201–205.
Seim H, Löster H, Claus R, Kleber H-P, and Strack E (1982b) Splitting of the C-N bond in
carnitine by an enzyme (trimethylamine forming) from membranes of Acinetobacter calcoace-
ticus. FEMS Microbiol Lett 15:165–167.
Seim H, Schulze J, and Strack E (1985) Catabolic pathways for high-dosed L(-)- or D(+)-carnitine
in germ-free rats? Biol Chem Hoppe Seyler 366:1017–1021.
Sellars MJ, Hall SJ, and Kelly DJ (2002) Growth of Campylobacter jejuni supported by respiration
of fumarate, nitrate, nitrite, trimethylamine-N-oxide, or dimethyl sulfoxide requires oxygen.
J Bacteriol 184:4187–4196.
Serra AL, Mariscotti JF, Barra JL, Lucchesi GI, Domenech CE, and Lisa AT (2002)
Glycine betaine transmethylase mutant of Pseudomonas aeruginosa. J Bacteriol 184:
4301–4303.
Shaw BG and Shewan JM (1968) Psychrophilic spoilage bacteria of fish. J Appl Bacteriol 31:
89–96.
Shephard EA, Treacy EP, and Phillips IR (2015) Clinical utility gene card for: Trimethylaminuria -
update 2014. Eur J Hum Genet DOI: 10.1038/ejhg.2014.226.
Shih DM, Wang Z, Lee R, Meng Y, Che N, Charugundla S, Qi H, Wu J, Pan C, Brown JM, et al.
(2015) Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism
and atherosclerosis. J Lipid Res 56:22–37.
Shimizu M, Allerston CK, Shephard EA, Yamazaki H, and Phillips IR (2014) Relationships
between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria pheno-
type in a Japanese population. Br J Clin Pharmacol 77:839–851.
Simenhoff ML, Saukkonen JJ, Burke JF, Wesson LG, and Schaedler RW (1976) Amine metab-
olism and the small bowel in uraemia. Lancet 2:818–821.
Söderberg MM, Haslemo T, Molden E, and Dahl M-L (2013) Influence of FMO1 and 3 poly-
morphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. Pharma-
cogenomics J 13:544–550.
Stenberg E, Styrvold OB, and Strøm AR (1982) Trimethylamine oxide respiration in Proteus sp.
strain NTHC153: electron transfer-dependent phosphorylation and L-serine transport. J Bacteriol
149:22–28.
Strøm AR, Olafsen JA, and Larsen H (1979) Trimethylamine oxide: a terminal electron acceptor in
anaerobic respiration of bacteria. J Gen Microbiol 112:315–320.
Takagi M, Tsuchiya T, and Ishimoto M (1981) Proton translocation coupled to trimethyl-
amine N-oxide reduction in anaerobically grown Escherichia coli. J Bacteriol 148:
762–768.
Takata Y, Zhang X, Li H, Gao Y-T, Yang G, Gao J, Cai H, Xiang Y-B, Zheng W, and Shu X-O
(2013) Fish intake and risks of total and cause-specific mortality in 2 population-based cohort
studies of 134,296 men and women. Am J Epidemiol 178:46–57.
Tang WHW, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS,
and Hazen SL (2015) Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway
contributes to both development of renal insufficiency and mortality risk in chronic kidney
disease. Circ Res 116:448–455.
Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, and Hazen SL (2013)
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med
368:1575–1584.
Tottey W, Denonfoux J, Jaziri F, Parisot N, Missaoui M, Hill D, Borrel G, Peyretaillade E,
Alric M, Harris HMB, et al. (2013) The human gut chip “HuGChip”, an explorative phy-
logenetic microarray for determining gut microbiome diversity at family level. PLoS One 8:
e62544.
Treacy EP, Akerman BR, Chow LML, Youil R, Bibeau C, Lin J, Bruce AG, Knight M,
Danks DM, Cashman JR, et al. (1998) Mutations of the flavin-containing monooxygenase
gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet 7:
839–845.
Ufnal M, Zadlo A, and Ostaszewski R (2015) TMAO: A small molecule of great expectations.
Nutrition 31:1317–1323.
Unemoto T, Hayashi M, Miyaki K, and Hayashi M (1965) Intracellular localization and properties
of trimethylamine-N-oxide reductase in Vibrio parahaemolyticus. Biochim Biophys Acta 110:
319–328.
Unemoto T, Hayashi M, Miyaki K, and Hayashi M (1966) Formation of trimethylamine from
DL-carnitine by Serratia marcescens. Biochim Biophys Acta 121:220–222.
Walker V and Wevers RA (2012) Trimethylaminuria and dimethylglycine dehydrogenase de-
ficiency, in Inborn Metabolic Diseases (Saudubray J-M, van den Berghe G, and Walker JH, eds)
pp 431–435, Springer, Berlin, Germany.
Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X,
Chung Y-M, et al. (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular
disease. Nature 472:57–63.
Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, Gu X, Huang Y, Zamanian-Daryoush
M, Culley MK, et al. (2015) Non-lethal inhibition of gut microbial trimethylamine production for
the treatment of atherosclerosis. Cell 163:1585–1595.
Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, Marshall S,
McDaniel A, Schugar RC, Wang Z, et al. (2015) The TMAO-generating enzyme flavin
monooxygenase 3 is a central regulator of cholesterol balance. Cell Reports 10:326–338.
Wilson A, Teft WA, Morse BL, Choi Y-H, Woolsey S, DeGorter MK, Hegele RA, Tirona RG,
and Kim RB (2015) Trimethylamine-N-oxide: A novel biomarker for the identification of in-
flammatory bowel disease. Dig Dis Sci 60:3620–3630.
Wise PM, Eades J, Tjoa S, Fennessey PV, and Preti G (2011) Individuals reporting idiopathic
malodor production: demographics and incidence of trimethylaminuria. Am J Med 124:
1058–1063.
Wolff JB (1962) Ergothionase from Escherichia coli. J Biol Chem 237:874–881.
TMA/TMAO, an FMO3-Mediated Host-Microbiome Metabolic Axis 1849
 at A









Wolrath H, Borén H, Hallén A, and Forsum U (2002) Trimethylamine content in vaginal secretion
and its relation to bacterial vaginosis. APMIS 110:819–824.
Wood AJ, Baird EA, and Keeping FE (1943) A primary division of the genus Shigella based on the
trimethylamine test. J Bacteriol 46:106–107.
Wood AJ and Keeping FE (1944) The formation of trimethylamine from choline as a characteristic
of Shigella alkalescens. J Bacteriol 47:309–310.
Wood AP, Warren FJ, and Kelly DP (2010) Methylotrophic bacteria in trimethylaminuria and
bacterial vaginosis, in Handbook of Hydrocarbon and Lipid Microbiology (Timmis KN,
McGenity TJ, van der Meer JR, and de Lorenzo V, eds) pp 3227–3240, Springer, Berlin,
Germany.
Xu R, Wang Q, and Li L (2015) A genome-wide systems analysis reveals strong link between
colorectal cancer and trimethylamine N-oxide (TMAO), a gut microbial metabolite of dietary
meat and fat. BMC Genomics 16 (Suppl 7):S4.
Yamazaki H and Shimizu M (2013) Survey of variants of human flavin-containing mono-
oxygenase 3 (FMO3) and their drug oxidation activities. Biochem Pharmacol 85:
1588–1593.
Yanasugondha D and Appleman MD (1957) Degradation of ergothioneine by Alcaligenes faecalis.
J Bacteriol 74:381–385.
Yang Y, Liu Y, Zheng L, Wu T, Li J, Zhang Q, Li X, Yuan F, Wang L, and Guo J (2014) Serum
metabonomic analysis of apoE(-/-) mice reveals progression axes for atherosclerosis based on
NMR spectroscopy. Mol Biosyst 10:3170–3178.
Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M,
Hidalgo G, Baldassano RN, Anokhin AP, et al. (2012) Human gut microbiome viewed across
age and geography. Nature 486:222–227.
Zeisel SH (1990) Choline deficiency. J Nutr Biochem 1:332–349.
Zeisel SH, daCosta KA, Youssef M, and Hensey S (1989) Conversion of dietary choline to
trimethylamine and dimethylamine in rats: dose-response relationship. J Nutr 119:
800–804.
Zeisel SH, Mar M-H, Howe JC, and Holden JM (2003) Concentrations of choline-containing
compounds and betaine in common foods. J Nutr 133:1302–1307.
Zeisel SH, Wishnok JS, and Blusztajn JK (1983) Formation of methylamines from ingested choline
and lecithin. J Pharmacol Exp Ther 225:320–324.
Zerbst-Boroffka I, Kamaltynow RM, Harjes S, Kinne-Saffran E, and Gross J (2005) TMAO and
other organic osmolytes in the muscles of amphipods (Crustacea) from shallow and deep water
of Lake Baikal. Comp Biochem Physiol A Mol Integr Physiol 142:58–64.
Zhang AQ, Mitchell SC, and Smith RL (1999) Dietary precursors of trimethylamine in man: a pilot
study. Food Chem Toxicol 37:515–520.
Zhou L-P, Tan Z-R, Chen H, Guo D, Chen Y, Huang W-H, Wang L-S, and Zhang G-G (2014)
Effect of two-linked mutations of the FMO3 gene on itopride metabolism in Chinese healthy
volunteers. Eur J Clin Pharmacol 70:1333–1338.
Zhu Y, Jameson E, Crosatti M, Schäfer H, Rajakumar K, Bugg TDH, and Chen Y (2014) Carnitine
metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota.
Proc Natl Acad Sci USA 111:4268–4273.
Zindel U, Freudenberg W, Rieth M, Andreesen JR, Schnell J, and Widdel F (1988) Eubacterium
acidaminophilum sp. nov., a versatile amino acid-degrading anaerobe producing or utilizing H2
or formate. Arch Microbiol 150:254–266.
Zoetendal EG, Rajilic-Stojanovic M, and de Vos WM (2008) High-throughput diversity and
functionality analysis of the gastrointestinal tract microbiota. Gut 57:1605–1615.
Zschocke J and Mayatepek E (2000) Biochemical and molecular studies in mild flavin mono-
oxygenase 3 deficiency. J Inherit Metab Dis 23:378–382.
Address correspondence to: Elizabeth A. Shephard, Institute of Structural and
Molecular Biology, University College London, London WC1E 6BT, UK. E-mail:
e.shephard@ucl.ac.uk
1850 Fennema et al.
 at A
SPET Journals on N
ovem
ber 9, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
